NCT03431350 2026-04-13
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT03748641 2026-04-13
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04497844 2026-04-13
AMPLITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04577833 2026-04-13
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05021562 2026-04-13
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Completed
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04037254 2026-04-06
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT06388733 2026-04-01
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed